Literature DB >> 20513856

An early improvement threshold to predict response and remission in first-episode schizophrenia.

Rebecca Schennach-Wolff1, Florian Hannes Seemüller, Andreas Mayr, Wolfgang Maier, Stefan Klingberg, Isabella Heuser, Joachim Klosterkötter, Markus Gastpar, Heinz Häfner, Heinrich Sauer, Frank Schneider, Wolfgang Gaebel, Markus Jäger, Hans-Jürgen Möller, Michael Riedel.   

Abstract

BACKGROUND: Early improvement with treatment is thought to be important in patients with first-episode schizophrenia, yet a valid definition is still outstanding. AIMS: To develop a valid definition of early improvement and test its predictive validity regarding response and remission.
METHOD: We examined 188 in-patients with first-episode schizophrenia. Early improvement was defined as improvement in Positive and Negative Syndrome Scale (PANSS) total score at week 2, response as a 40% PANSS total score improvement at end-point, and remission according to consensus criteria.
RESULTS: Reasonable predictive validity of early improvement was found for a 46% PANSS total score improvement at week 2 and a 50% improvement for remission (area under the curve: response 0.707, remission 0.692). Estimated confidence intervals ranged from 26 to 62% PANSS reduction for response and remission.
CONCLUSIONS: Patients with a first episode of schizophrenia should improve by at least 30% in PANSS total score at week 2 to achieve response and remission.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20513856     DOI: 10.1192/bjp.bp.109.069328

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  12 in total

1.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

2.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

Review 3.  Is the PANSS used correctly? a systematic review.

Authors:  Michael Obermeier; Rebecca Schennach-Wolff; Sebastian Meyer; Hans-Jürgen Möller; Michael Riedel; Daniela Krause; Florian Seemüller
Journal:  BMC Psychiatry       Date:  2011-07-18       Impact factor: 3.630

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

5.  Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.

Authors:  JunJie Wang; TianHong Zhang; LiHua Xu; YanYan Wei; XiaoChen Tang; YeGang Hu; HuiRu Cui; YingYing Tang; ChunBo Li; Zheng Ling; JiJun Wang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-09-18       Impact factor: 5.270

6.  Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.

Authors:  Marie Stentebjerg-Olesen; Pia Jeppesen; Anne K Pagsberg; Anders Fink-Jensen; Sandeep Kapoor; Raja Chekuri; Maren Carbon; Aseel Al-Jadiri; Taishiro Kishimoto; John M Kane; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-11-22       Impact factor: 2.576

7.  Treatment Response in First-episode Schizophrenia.

Authors:  Rebecca Schennach; Michael Riedel; Richard Musil; Hans-Jürgen Möller
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

8.  Predicting functional remission in patients with schizophrenia: a cross-sectional study of symptomatic remission, psychosocial remission, functioning, and clinical outcome.

Authors:  Marcelo Valencia; Ana Fresán; Yoram Barak; Francisco Juárez; Raul Escamilla; Ricardo Saracco
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-10       Impact factor: 2.570

9.  A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.

Authors:  Arantzazu Zabala; Mariana Bustillo; Imanol Querejeta; Marta Alonso; Oiane Mentxaka; Ana González-Pinto; Amaia Ugarte; J Javier Meana; Miguel Gutiérrez; Rafael Segarra
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

10.  Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate.

Authors:  Kara Dempster; Peter Jeon; Michael MacKinley; Peter Williamson; Jean Théberge; Lena Palaniyappan
Journal:  Mol Psychiatry       Date:  2020-03-24       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.